Event Information

Event Topic:
Developing curative treatments for Idiopathic Pulmonary Fibrosis.

Event Description:
Idiopathic pulmonary fibrosis (IPF) is an invariably fatal lung disease characterized by progressive scarring of the lungs, resulting in respiratory failure. It affects about 100,000 patients in US alone. Approximately 40,000 Americans die each year from IPF. An average life expectancy after diagnosis is only 3 years (5 years with lung transplant). There are two treatments currently approved for IPF, pirfenidone (Genetech) and nintedanib (Boehringer Ingelheim). However, these therapeutics only slow but not reverse the disease progression. The causes of IPF remain unknown but they involve combination of genetic and environmental factors. While only some IPF patients have mutations in telomerase, all IPF patients have short telomeres. An accumulating evidence suggest that short telomeres may cause IPF, and the disease progression may be reversed by increasing telomerase activity and stabilizing telomeres. We will discuss strategies for developing telomerase-based IPF therapies.

Date/Time:
Date(s) - 09/14/21
6:30 pm - 8:30 pm

Event Location:
Zoom talk: https://us02web.zoom.us/j/88274227563:

Speaker Information

Event Speaker:
Alexey Bazarov

Event Speaker Title:
Founder & CEO

Event Speaker Company:
Enlil Therapeutics

Event Speaker Bio:

Dr. Bazarov received B.S. in Biochemistry from Cornell University and Ph.D. in Molecular Biophysics and Biochemistry from Yale. His academic research in UCSF and Lawrence Berkeley National Laboratory focused on telomerase regulation in earlier stages of breast cancer progression. Dr. Bazarov is a co-inventor on 21 issued patents. Prior to founding Enlil Therapeutics in 2017, he was a first employee in three startups.

Event Details

Cost:
$0

Add To Calendar